Phase I clinical trial project of YK012 for injection was officially launched
2023-02-07 10:17:34 admin 23
After seven years of sharpening, the phase I clinical trial of YK012 for injection was officially launched recently.
YK012 for injection is a new generation of safe, high-yield, long-acting and low-cost bispecific antibody drug independently developed by our company for the treatment of non-Hodgkin's lymphoma (NHL), which belongs to innovative class 1 new drug. We will continue to work hard to achieve the early listing of YK012 for injection at home and abroad and benefit tumor patients!